Author: Mazzeffi, Michael A.; Chow, Jonathan H.; Tanaka, Kenichi
Title: COVID-19 Associated Hypercoagulability: Manifestations, Mechanisms, and Management Cord-id: rqkl24hf Document date: 2020_9_2
ID: rqkl24hf
Snippet: Patients with severe coronavirus disease-2019 (COVID-19) frequently have hypercoagulability caused by the immune response to the severe acute respiratory syndrome coronavirus-2 infection. The pathophysiology of COVID-19 associated hypercoagulability is not fully understood, but characteristic changes include: increased fibrinogen concentration, increased Factor VIII activity, increased circulating von Willebrand factor, and exhausted fibrinolysis. Anticoagulant therapy improves outcomes in mecha
Document: Patients with severe coronavirus disease-2019 (COVID-19) frequently have hypercoagulability caused by the immune response to the severe acute respiratory syndrome coronavirus-2 infection. The pathophysiology of COVID-19 associated hypercoagulability is not fully understood, but characteristic changes include: increased fibrinogen concentration, increased Factor VIII activity, increased circulating von Willebrand factor, and exhausted fibrinolysis. Anticoagulant therapy improves outcomes in mechanically ventilated patients with COVID-19 and viscoelastic coagulation testing offers an opportunity to tailor anticoagulant therapy based on an individual patient's coagulation status. In this narrative review, we summarize clinical manifestations of COVID-19, mechanisms, monitoring considerations, and anticoagulant therapy. We also review unique considerations for COVID-19 patients who are on extracorporeal membrane oxygenation.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and adequately analysis: 1
- acute respiratory syndrome and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and adjunctive treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute respiratory syndrome and logical treatment: 1, 2
- acute respiratory syndrome and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low appear: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory syndrome and low intensity: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory syndrome and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low molecular weight heparin vte prophylaxis: 1, 2
- acute respiratory syndrome and low normal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acute respiratory syndrome and low probably: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adjunctive therapy and low molecular: 1
- adjunctive therapy and low molecular weight heparin: 1
- adjunctive treatment and low molecular: 1
- adjunctive treatment and low molecular weight heparin: 1
- adjunctive treatment and low normal: 1
- long duration and low appear: 1
- long duration and low intensity: 1
Co phrase search for related documents, hyperlinks ordered by date